United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

10:13am EDT
Change (% chg)

€-0.70 (-0.63%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IPN.PA


Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care... (more)


Beta: 0.70
Market Cap(Mil.): €9,231.47
Shares Outstanding(Mil.): 83.58
Dividend: 0.85
Yield (%): 0.77


  IPN.PA Industry Sector
P/E (TTM): 40.46 14.35 17.42
EPS (TTM): 2.73 -- --
ROI: 13.48 -7.29 -5.45
ROE: 17.49 -6.80 -4.73

BRIEF-Ipsen sees 2020 sales to exceed 2.5 billion euros


May 11 2017

BRIEF-Ipsen Q1 sales up 19.1 pct at 438.0 million euros

* Q1 sales 438.0 million euros ($477.68 million) versus 362.0 million euros year ago

Apr 27 2017

BRIEF-Merrimack declares $140 mln special dividend

* Merrimack declares $140 mln special dividend in connection with recently completed asset sale

Apr 05 2017

BRIEF-Ipsen announces Health Canada approval of dysport therapeutic for treatment of patients with cervical dystonia

* Ipsen announces health canada approval of dysport therapeutic™ (abobotulinumtoxina) for the treatment of patients with cervical dystonia and adult upper limb spasticity Source text for Eikon: Further company coverage:

Mar 14 2017

BRIEF-Ipsen FY net profit rises to 226.6 million euros

* Delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

Feb 23 2017

BRIEF-Ipsen acquires a portfolio of select consumer healthcare products from Sanofi

* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

Feb 13 2017

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

Feb 13 2017

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

Feb 12 2017

BRIEF-Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma

* Ipsen to acquire Primary Care Platform in Italy from Akkadeas Pharma

Jan 31 2017

France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal

French drugmaker Ipsen SA said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc , including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial.

Jan 09 2017

More From Around the Web

Earnings vs. Estimates